Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -79.35% | -83.93% | 95.42% | 176.17% | 225.25% |
| Depreciation & Amortization | 130.41% | 405.84% | 256.85% | 554.90% | 232.29% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.74% | -75.28% | 48.37% | 82.75% | 76.43% |
| Operating Income | 76.74% | 75.28% | -48.37% | -82.75% | -76.43% |
| Income Before Tax | 73.59% | 70.43% | -56.21% | -89.63% | -84.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.38% | 70.20% | -58.48% | -92.56% | -83.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.38% | 70.20% | -58.48% | -92.56% | -83.30% |
| EBIT | 76.74% | 75.28% | -48.37% | -82.75% | -76.43% |
| EBITDA | 77.30% | 75.97% | -47.63% | -146.19% | -303.07% |
| EPS Basic | 74.81% | 71.48% | -46.24% | -69.73% | -55.67% |
| Normalized Basic EPS | 74.08% | 71.72% | -44.18% | -67.24% | -56.66% |
| EPS Diluted | 74.81% | 71.48% | -46.24% | -69.73% | -55.67% |
| Normalized Diluted EPS | 74.08% | 71.72% | -44.18% | -67.24% | -56.66% |
| Average Basic Shares Outstanding | 6.05% | 6.96% | 9.85% | 13.67% | 17.21% |
| Average Diluted Shares Outstanding | 6.05% | 6.96% | 9.85% | 13.67% | 17.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |